These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22951888)

  • 1. Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
    Pollin TI; Isakova T; Jablonski KA; de Bakker PI; Taylor A; McAteer J; Pan Q; Horton ES; Delahanty LM; Altshuler D; Shuldiner AR; Goldberg RB; Florez JC; Franks PW;
    PLoS Genet; 2012; 8(8):e1002895. PubMed ID: 22951888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.
    Varga TV; Winters AH; Jablonski KA; Horton ES; Khare-Ranade P; Knowler WC; Marcovina SM; Renström F; Watson KE; Goldberg R; Florez JC; Pollin TI; Franks PW
    Circ Cardiovasc Genet; 2016 Dec; 9(6):495-503. PubMed ID: 27784733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
    Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
    Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
    Goldberg R; Temprosa M; Otvos J; Brunzell J; Marcovina S; Mather K; Arakaki R; Watson K; Horton E; Barrett-Connor E
    J Clin Endocrinol Metab; 2013 Oct; 98(10):3989-98. PubMed ID: 23979954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.
    Hivert MF; Jablonski KA; Perreault L; Saxena R; McAteer JB; Franks PW; Hamman RF; Kahn SE; Haffner S; ; Meigs JB; Altshuler D; Knowler WC; Florez JC;
    Diabetes; 2011 Apr; 60(4):1340-8. PubMed ID: 21378175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Fat mass and obesity associated' gene (FTO): no significant association of variant rs9939609 with weight loss in a lifestyle intervention and lipid metabolism markers in German obese children and adolescents.
    Müller TD; Hinney A; Scherag A; Nguyen TT; Schreiner F; Schäfer H; Hebebrand J; Roth CL; Reinehr T
    BMC Med Genet; 2008 Sep; 9():85. PubMed ID: 18799002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
    Salimi Y; Fotouhi A; Mohammad K; Mansournia N; Mansournia MA
    Arch Iran Med; 2017 Jan; 20(1):55-59. PubMed ID: 28112533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combined Effect of Common Genetic Risk Variants on Circulating Lipoproteins Is Evident in Childhood: A Longitudinal Analysis of the Cardiovascular Risk in Young Finns Study.
    Buscot MJ; Magnussen CG; Juonala M; Pitkänen N; Lehtimäki T; Viikari JS; Kähönen M; Hutri-Kähönen N; Schork NJ; Raitakari OT; Thomson RJ
    PLoS One; 2016; 11(1):e0146081. PubMed ID: 26731281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors.
    Shatwan IM; Winther KH; Ellahi B; Elwood P; Ben-Shlomo Y; Givens I; Rayman MP; Lovegrove JA; Vimaleswaran KS
    Lipids Health Dis; 2018 Apr; 17(1):98. PubMed ID: 29712557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.
    Florez JC; Jablonski KA; McAteer JB; Franks PW; Mason CC; Mather K; Horton E; Goldberg R; Dabelea D; Kahn SE; Arakaki RF; Shuldiner AR; Knowler WC;
    PLoS One; 2012; 7(9):e44424. PubMed ID: 22984506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2 Diabetes and Adiposity Induce Different Lipid Profile Disorders: A Mendelian Randomization Analysis.
    Wang N; Cheng J; Ning Z; Chen Y; Han B; Li Q; Chen C; Zhao L; Xia F; Lin D; Guo L; Lu Y
    J Clin Endocrinol Metab; 2018 May; 103(5):2016-2025. PubMed ID: 29506267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles.
    Amor AJ; Castelblanco E; Hernández M; Gimenez M; Granado-Casas M; Blanco J; Soldevila B; Esmatjes E; Conget I; Alonso N; Ortega E; Mauricio D
    Cardiovasc Diabetol; 2020 Aug; 19(1):126. PubMed ID: 32772924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg/dl and non-high-density lipoprotein cholesterol <80 mg/dl.
    Malave H; Castro M; Burkle J; Voros S; Dayspring T; Honigberg R; Pourfarzib R
    Am J Cardiol; 2012 Sep; 110(5):662-5. PubMed ID: 22621796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
    Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
    Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of Lipid Genetic Risk Scores With Estimates of Metabolic Health in a Danish Population.
    Justesen JM; Allin KH; Sandholt CH; Borglykke A; Krarup NT; Grarup N; Linneberg A; Jørgensen T; Hansen T; Pedersen O
    Circ Cardiovasc Genet; 2015 Jun; 8(3):465-72. PubMed ID: 25714099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people.
    Murray A; Cluett C; Bandinelli S; Corsi AM; Ferrucci L; Guralnik J; Singleton A; Frayling T; Melzer D
    Eur Heart J; 2009 Jul; 30(14):1711-9. PubMed ID: 19435741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shared common variants in prostate cancer and blood lipids.
    Andreassen OA; Zuber V; Thompson WK; Schork AJ; Bettella F; ; ; Djurovic S; Desikan RS; Mills IG; Dale AM
    Int J Epidemiol; 2014 Aug; 43(4):1205-14. PubMed ID: 24786909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.